COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health South Florida today announced new study results validating the artificial intelligence (AI)-enabled PreciseBreast™ test is equivalent to the Oncotype DX test at predicting breast cancer recurrence.